Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers - PubMed (original) (raw)
Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers
Kara Lee Shirley et al. Neuropsychopharmacology. 2003 May.
Abstract
Olanzapine has previously been shown to have predominant metabolism by cytochrome (CYP) P450 1A2. Caffeine has been shown to provide an accurate phenotypic probe for measuring CYP1A2 activity. The purpose of this study is to determine if a significant correlation exists between olanzapine disposition and caffeine metabolic ratios. Subjects were phenotyped for CYP1A2 activity with caffeine probe methodology. After 200-mg caffeine administration, blood (4 h), saliva (6 and 10 h), and urine (8 h total) were collected for high-performance liquid chromatography (HPLC) analysis of caffeine and its metabolites.CYP1A2 activity was measured as plasma (PMR(4 h)), saliva (SMR(6 h) and SMR(10 h)), and three urinary metabolic (UMR1(8 h), UMR2(8 h), and UMR3(8 h)) ratios. Each of the 14 healthy nonsmokers (13 male) received a single 10 mg olanzapine dose after which blood was collected for HPLC determination of olanzapine concentrations at predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, and 120 h postdose. Olanzapine pharmacokinetic parameters in this study were similar to those previously published. All caffeine metabolic ratios (PMR(4 h), SMR(6 h), SMR(10 h), UMR1(8 h), and UMR2(8 h)) significantly correlated with each other (p <0.001) except for UMR3(8 h), which did not correlate. A significant correlation (p <0.05) was also found between olanzapine clearance and PMR(4 h) (r=0.701), SMR(6 h) (r=0.644), SMR(10 h) (r=0.701), UMR1(8 h) (r=0.745), and UMR2(8 h) (r=0.710). A negative correlation was observed between olanzapine clearance and UMR3(8 h) (r=-0.029, p=NS). A significant correlation was found between olanzapine clearance and various caffeine metabolic ratios. Interpatient variability in CYP1A2 activity may explain the wide interpatient variability in olanzapine disposition. Compounds that modulate CYP1A2 activity may be expected to alter olanzapine pharmacokinetics accordingly.
Similar articles
- Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.
Hägg S, Spigset O, Lakso HA, Dahlqvist R. Hägg S, et al. Eur J Clin Pharmacol. 2001 Sep;57(6-7):493-7. doi: 10.1007/s002280100343. Eur J Clin Pharmacol. 2001. PMID: 11699614 Clinical Trial. - Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Carrillo JA, Herráiz AG, Ramos SI, Gervasini G, Vizcaíno S, Benítez J. Carrillo JA, et al. J Clin Psychopharmacol. 2003 Apr;23(2):119-27. doi: 10.1097/00004714-200304000-00003. J Clin Psychopharmacol. 2003. PMID: 12640212 Clinical Trial. - Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH. Fuhr U, et al. Pharmacogenetics. 1996 Apr;6(2):159-76. doi: 10.1097/00008571-199604000-00003. Pharmacogenetics. 1996. PMID: 9156694 - Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Callaghan JT, et al. Clin Pharmacokinet. 1999 Sep;37(3):177-93. doi: 10.2165/00003088-199937030-00001. Clin Pharmacokinet. 1999. PMID: 10511917 Review. - [On the possibility of patient phenotyping on the basis of cytochrome p-450 1A2 isoenzyme activity using caffeine as the test substrate].
Filimonova AA, Ziganshina LE, Ziganshin AU, Chichirov AA. Filimonova AA, et al. Eksp Klin Farmakol. 2009 Sep-Oct;72(5):61-5. Eksp Klin Farmakol. 2009. PMID: 19928580 Review. Russian.
Cited by
- Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?
Schwenger E, Dumontet J, Ensom MH. Schwenger E, et al. Clin Pharmacokinet. 2011 Jul;50(7):415-28. doi: 10.2165/11587240-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21651311 Review. - Clinical applications of CYP genotyping in psychiatry.
Spina E, de Leon J. Spina E, et al. J Neural Transm (Vienna). 2015 Jan;122(1):5-28. doi: 10.1007/s00702-014-1300-5. Epub 2014 Sep 9. J Neural Transm (Vienna). 2015. PMID: 25200585 Review. - A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.
Nguyen TT, Bénech H, Pruvost A, Lenuzza N. Nguyen TT, et al. Eur J Clin Pharmacol. 2016 Jan;72(1):39-51. doi: 10.1007/s00228-015-1953-5. Eur J Clin Pharmacol. 2016. PMID: 26490357 Clinical Trial. - Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM, Lambert WE, Stove CP. De Kesel PM, et al. Clin Pharmacokinet. 2015 Jul;54(7):771-81. doi: 10.1007/s40262-015-0237-7. Clin Pharmacokinet. 2015. PMID: 25603821 - Population pharmacokinetics of olanzapine in children.
Maharaj AR, Wu H, Zimmerman KO, Autmizguine J, Kalra R, Al-Uzri A, Sherwin CMT, Goldstein SL, Watt K, Erinjeri J, Payne EH, Cohen-Wolkowiez M, Hornik CP. Maharaj AR, et al. Br J Clin Pharmacol. 2021 Feb;87(2):542-554. doi: 10.1111/bcp.14414. Epub 2020 Jul 5. Br J Clin Pharmacol. 2021. PMID: 32497307 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous